No Data
The Past Three Years for Intellia Therapeutics (NASDAQ:NTLA) Investors Has Not Been Profitable
Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Intellia Therapeutics, Inc. (
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company's impressive second
Intellia Therapeutics(NTLA.US) Officer Sells US$9,286.65 in Common Stock
$Intellia Therapeutics(NTLA.US)$ Officer Clark Eliana sold 405 shares of common stock on Jul 1, 2024 at an average price of $22.93 for a total value of $9,286.65.Source: Announcement What is statement
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Tec
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $24 to $73
On Jun 27, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $24 to $73.BMO Capital analyst Kostas Biliouris maintains with a buy ra